Developer docs
API playgroundTry for free, no card

Search company profiles

Palleon Pharmaceuticals

Full company profile

uuid0000efk

Namestring
Palleon Pharmaceuticals
Legal namestring
Palleon Pharmaceuticals Inc.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Palleon Pharmaceuticals is a clinical-stage biotherapeutics company developing first-in-class glyco-immune checkpoint inhibitors to treat cancer and autoimmune diseases. The company's scientific premise is that tumor hypersialylation — the overabundance of immunosuppressive sialic acid sugars on cell surfaces — drives resistance to existing immunotherapies. Palleon's lead asset, E-602 (Efgitasialase alfa), is an engineered human sialidase fusion protein that enzymatically removes these immunosuppressive sialic acids from tumor and immune cell surfaces, restoring anti-tumor immunity; it is currently in a Phase 2 trial in membranous nephropathy and was previously studied in the Phase 1/2 GLIMMER-01 solid tumor study. A second clinical asset, E-688/HLX316, is a B7-H3-targeted sialidase developed using the EAGLE (Enzyme-Antibody Glycan-Ligand Editing) platform and entered Phase 1 in 2026 in China via partner Henlius.

The company operates a platform-based model anchored on three proprietary technologies: EAGLE for designing enzyme-antibody bi-specific therapeutics, CONVERGENCE for integrating glycoscience and immunology discovery, and HYDRA for patient stratification via tumor glyco-code profiling. Palleon is pre-revenue and does not commercialize products; revenue will derive from future drug commercialization and from milestone payments and royalties under the 2022 strategic collaboration with Shanghai Henlius Biotech, which provides Henlius China rights to two bifunctional sialidase programs in exchange for upfront consideration and up to $196.5 million in development and commercial milestones. Its customer base consists of patients enrolled in clinical trials at academic medical centers, and its GTM motion relies on scientific conferences (AACR, SITC, ASN, ACR), FDA/NMPA regulatory engagement, and partnership-led commercialization rather than direct sales.

Palleon was founded in 2015 by Jim Broderick (formerly partner at Morgenthaler Ventures and co-founder of Ra Pharmaceuticals) together with Nobel laureate Carolyn Bertozzi and Siglec biology pioneer Paul Crocker, and is headquartered in Waltham, Massachusetts. The company has raised $147.6 million in venture capital across a $47.6M Series A (2017, SR One-led) and a $100M Series B (2020, Matrix Capital Management-led), with strategic investors including Pfizer Ventures, Takeda Ventures, AbbVie Ventures, Vertex Ventures HC, and Surveyor Capital.

Short descriptiontext

Palleon Pharmaceuticals is a clinical-stage biotherapeutics company developing first-in-class engineered sialidase therapies that remove immunosuppressive sialoglycans to treat cancer and autoimmune diseases, with two clinical-stage assets (E-602 and E-688/HLX316).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
glyco-immune checkpoint inhibitors, engineered sialidase therapeutics, immuno-oncology drug development, autoimmune disease therapeutics, biopharmaceutical drug discovery
Industry3 codes
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Biopharmaceuticals - Glyco-immune Checkpoint Inhibitors
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Commercialization
TypeOne Time License
Description

Palleon Pharmaceuticals is a clinical-stage biotherapeutics company with no current revenue. The company is developing novel therapeutics for cancer and autoimmune diseases. Future revenue would come from commercialized drug products following regulatory approval.

biospace.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Palleon Pharmaceuticals is a clinical-stage biopharmaceutical company developing first-in-class glyco-immune checkpoint inhibitors for the treatment of cancer and autoimmune diseases. The company uses proprietary engineered human sialidase enzymes (via the EAGLE, CONVERGENCE, and HYDRA platforms) to enzymatically remove immunosuppressive sialic acids from tumor and immune cell surfaces, restoring anti-tumor immunity. Lead clinical assets include E-602 (Phase 2 for membranous nephropathy/autoimmune disease; previously Phase 1/2 for solid tumors) and E-688/HLX316 (Phase 1 for advanced solid tumors in China).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • E-602 demonstrated single-agent antitumor activity and wide safety margin in animal models with NOAEL of 100 mg/kg in non-human primates
+3 more records
Product overview1 text field

Palleon Pharmaceuticals is a clinical-stage biotechnology company pioneering glyco-immunology drug development to treat cancer and autoimmune diseases. The company operates a platform-based approach with three proprietary technology platforms: EAGLE (Enzyme-Antibody Glycan-Editing) for creating enzyme-antibody bifunctional therapeutics, HYDRA for patient selection via tumor glycan profiling, and CONVERGENCE for integrating glycoscience and immunology expertise. The lead clinical programs are E-602 (Efgitasialase alfa), a first-in-class bi-sialidase fusion protein now in Phase 2 for membranous nephropathy/autoimmune disease, and E-688/HLX316, a first-in-class B7-H3-targeted sialidase in Phase 1 for solid tumors. Additional pipeline candidates include bifunctional PD-L1-targeted sialidase and anti-Siglec-9 antibodies. The company's approach targets immunosuppressive sialoglycans on cell surfaces to restore immune responses. Founded in 2015, Palleon was co-founded by Nobel laureate Carolyn Bertozzi.

Product and service2 records
1E-602 (Efgitasialase alfa)
CategoryClinical-stage Biopharmaceutical - Lead Immuno-oncology and Autoimmune Asset
Description

First-in-class engineered human sialidase enzyme fusion protein (bi-sialidase) that degrades immunosuppressive sialoglycans on tumor and immune cell surfaces, restoring both innate and adaptive anti-tumor immunity. Previously known as Sialidase-Fc and Bi-Sialidase. In Phase 2 development for membranous nephropathy and lupus nephritis (autoimmune kidney disease), previously in Phase 1/2 GLIMMER-01 for solid tumors (NCT05259696). Being developed in combination with rituximab biosimilar and with anti-PD-1 antibodies (pembrolizumab/cemiplimab).

2E-688/HLX316
CategoryClinical-stage Biopharmaceutical - Tumor-targeted Sialidase Asset
Description

First-in-class B7-H3-targeted sialidase combining human sialidase enzyme with targeting arm directed at B7-H3 tumor antigen. Engineered using the EAGLE Platform for tumor-targeted enzymatic desialylation. In Phase 1 clinical trial for advanced solid tumors (platinum-resistant ovarian cancer) conducted in China via strategic partner Henlius. Demonstrated tumor surface desialylation lasting more than seven days in vivo and outperformed anti-PD-1 as single agent in humanized tumor models.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Shanghai Henlius Biotech
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-28
Description

Strategic collaboration to develop and commercialize two bifunctional sialidase programs from Palleon's EAGLE platform, including Bifunctional HER2-Sialidase and a second bifunctional sialidase. Henlius received exclusive license for two products in China (including Hong Kong, Macau, and Taiwan); Palleon retains all other global rights. Palleon received upfront payment and is eligible for up to $196.5 million in milestone payments plus royalties.

palleonpharma.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-04-09
Description

Research collaboration using Palleon's HYDRA technology to quantify immunosuppressive sialoglycans in melanoma tumor samples.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2017-12-12
Description

Exclusive license agreement for intellectual property developed by Professor Joy Burchell related to glycoimmune checkpoints for treating cancer. Professor Burchelli has been a leader in aberrant glycosylation in breast cancer for over 25 years.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Innate Pharma
TypeDirect peer
Description

Clinical-stage immuno-oncology company developing antibody-based therapeutics targeting innate immune cells. Comparable to Palleon in stage, I/O modality innovation, and European/U.S. clinical focus, though Innate targets NK and myeloid checkpoints rather than glyco-immune checkpoints.

TypeDirect peer
Description

Clinical-stage oncology biotech developing tumor-activated immunotherapies (PREDATOR platform) that conditionally activate within the tumor microenvironment. Comparable to Palleon in its I/O modality innovation approach and clinical-stage development profile.

TypeDirect peer
Description

Clinical-stage oncology company developing novel antibodies for I/O, including bispecifics and antibody-drug conjugates. Similar in clinical-stage development, novel checkpoint engagement, and I/O competitive positioning to Palleon's EAGLE platform output.

TypeDirect peer
Description

Clinical-stage biotech developing tumor-activated immunotherapies (including masked cytokines and bispecifics) that are designed to be activated selectively in the tumor microenvironment. Directly comparable clinical-stage I/O peer with similar novel-modality approach.

5Surface Oncology
TypeDirect peer
Description

Clinical-stage immuno-oncology company developing antibodies targeting novel immune checkpoints (CD39, CD73, IL-27). Comparable in clinical stage and focus on next-generation checkpoint mechanisms beyond PD-1/L1, though Surface targets the adenosine pathway rather than glycans.

TypeDirect peer
Description

Clinical-stage biotech developing engineered cytokine therapeutics (selective IL-2 and IL-15 agonists) for cancer immunotherapy. Comparable as a clinical-stage I/O company engineering novel immunomodulatory biologics, with similar size and development profile.

TypeDirect peer
Description

Clinical-stage oncology company developing antibody-drug conjugates and immunotherapies. Comparable clinical-stage peer in novel oncology therapeutic modalities, though Pyxis focuses on ADCs rather than enzyme-based glyco-immune approaches.

TypeDirect peer
Description

Clinical-stage immunology company developing antibodies targeting the innate immune system for neurodegeneration and oncology. Comparable as a science-driven immunology platform company with deep academic founder involvement, though Alector primarily targets neurodegenerative diseases.

TypeBroad incumbent
Description

Established antibody therapeutics company with approved products (Darzalex, Tepezza) and broad I/O pipeline. Relevant as a broader incumbent in antibody-based I/O modalities that competes for the same BD, talent, and capital pools as Palleon's bifunctional sialidase programs.

TypeEmerging player
Description

Clinical-stage biotech developing therapeutics for hematologic diseases with novel mechanisms. Comparable as a similar-sized, science-led clinical-stage biotech with a focus on hematology-adjacent indications, though Disc targets erythroid biology rather than glyco-immune checkpoints.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Palleon Pharmaceuticals

Clinical-stage Biopharmaceuticals - Glyco-immune Checkpoint Inhibitorspalleonpharma.com

Palleon Pharmaceuticals is a clinical-stage biotherapeutics company developing first-in-class engineered sialidase therapies that remove immunosuppressive sialoglycans to treat cancer and autoimmune diseases, with two clinical-stage assets (E-602 and E-688/HLX316).

What Palleon Pharmaceuticals does

Palleon Pharmaceuticals is a clinical-stage biotherapeutics company developing first-in-class glyco-immune checkpoint inhibitors to treat cancer and autoimmune diseases. The company's scientific premise is that tumor hypersialylation — the overabundance of immunosuppressive sialic acid sugars on cell surfaces — drives resistance to existing immunotherapies. Palleon's lead asset, E-602 (Efgitasialase alfa), is an engineered human sialidase fusion protein that enzymatically removes these immunosuppressive sialic acids from tumor and immune cell surfaces, restoring anti-tumor immunity; it is currently in a Phase 2 trial in membranous nephropathy and was previously studied in the Phase 1/2 GLIMMER-01 solid tumor study. A second clinical asset, E-688/HLX316, is a B7-H3-targeted sialidase developed using the EAGLE (Enzyme-Antibody Glycan-Ligand Editing) platform and entered Phase 1 in 2026 in China via partner Henlius.

The company operates a platform-based model anchored on three proprietary technologies: EAGLE for designing enzyme-antibody bi-specific therapeutics, CONVERGENCE for integrating glycoscience and immunology discovery, and HYDRA for patient stratification via tumor glyco-code profiling. Palleon is pre-revenue and does not commercialize products; revenue will derive from future drug commercialization and from milestone payments and royalties under the 2022 strategic collaboration with Shanghai Henlius Biotech, which provides Henlius China rights to two bifunctional sialidase programs in exchange for upfront consideration and up to $196.5 million in development and commercial milestones. Its customer base consists of patients enrolled in clinical trials at academic medical centers, and its GTM motion relies on scientific conferences (AACR, SITC, ASN, ACR), FDA/NMPA regulatory engagement, and partnership-led commercialization rather than direct sales.

Palleon was founded in 2015 by Jim Broderick (formerly partner at Morgenthaler Ventures and co-founder of Ra Pharmaceuticals) together with Nobel laureate Carolyn Bertozzi and Siglec biology pioneer Paul Crocker, and is headquartered in Waltham, Massachusetts. The company has raised $147.6 million in venture capital across a $47.6M Series A (2017, SR One-led) and a $100M Series B (2020, Matrix Capital Management-led), with strategic investors including Pfizer Ventures, Takeda Ventures, AbbVie Ventures, Vertex Ventures HC, and Surveyor Capital.

Palleon Pharmaceuticals firmographics

Firmographics
Name
Palleon Pharmaceuticals
Legal name
Palleon Pharmaceuticals Inc.
Website
https://palleonpharma.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Palleon Pharmaceuticals is a clinical-stage biotherapeutics company developing first-in-class engineered sialidase therapies that remove immunosuppressive sialoglycans to treat cancer and autoimmune diseases, with two clinical-stage assets (E-602 and E-688/HLX316).
Ownership category
akta.pro rank

Palleon Pharmaceuticals industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals - Glyco-immune Checkpoint Inhibitors
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals

Keywords

  • Glyco-immune checkpoint inhibitors
  • Engineered sialidase therapeutics
  • Immuno-oncology drug development
  • Autoimmune disease therapeutics
  • Biopharmaceutical drug discovery

Where Palleon Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Palleon Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Development and Commercialization: Palleon Pharmaceuticals is a clinical-stage biotherapeutics company with no current revenue. The company is developing novel therapeutics for cancer and autoimmune diseases. Future revenue would come from commercialized drug products following regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Palleon Pharmaceuticals product offering

Product offering

Core offering

Palleon Pharmaceuticals is a clinical-stage biopharmaceutical company developing first-in-class glyco-immune checkpoint inhibitors for the treatment of cancer and autoimmune diseases. The company uses proprietary engineered human sialidase enzymes (via the EAGLE, CONVERGENCE, and HYDRA platforms) to enzymatically remove immunosuppressive sialic acids from tumor and immune cell surfaces, restoring anti-tumor immunity. Lead clinical assets include E-602 (Phase 2 for membranous nephropathy/autoimmune disease; previously Phase 1/2 for solid tumors) and E-688/HLX316 (Phase 1 for advanced solid tumors in China).

Product overview

Palleon Pharmaceuticals is a clinical-stage biotechnology company pioneering glyco-immunology drug development to treat cancer and autoimmune diseases. The company operates a platform-based approach with three proprietary technology platforms: EAGLE (Enzyme-Antibody Glycan-Editing) for creating enzyme-antibody bifunctional therapeutics, HYDRA for patient selection via tumor glycan profiling, and CONVERGENCE for integrating glycoscience and immunology expertise. The lead clinical programs are E-602 (Efgitasialase alfa), a first-in-class bi-sialidase fusion protein now in Phase 2 for membranous nephropathy/autoimmune disease, and E-688/HLX316, a first-in-class B7-H3-targeted sialidase in Phase 1 for solid tumors. Additional pipeline candidates include bifunctional PD-L1-targeted sialidase and anti-Siglec-9 antibodies. The company's approach targets immunosuppressive sialoglycans on cell surfaces to restore immune responses. Founded in 2015, Palleon was co-founded by Nobel laureate Carolyn Bertozzi.

Differentiator

Problem solved

Functional benefit

Products and services

  • E-602 (Efgitasialase alfa) First-in-class engineered human sialidase enzyme fusion protein (bi-sialidase) that degrades immunosuppressive sialoglycans on tumor and immune cell surfaces, restoring both innate and adaptive anti-tumor immunity. Previously known as Sialidase-Fc and Bi-Sialidase. In Phase 2 development for membranous nephropathy and lupus nephritis (autoimmune kidney disease), previously in Phase 1/2 GLIMMER-01 for solid tumors (NCT05259696). Being developed in combination with rituximab biosimilar and with anti-PD-1 antibodies (pembrolizumab/cemiplimab).
  • E-688/HLX316 First-in-class B7-H3-targeted sialidase combining human sialidase enzyme with targeting arm directed at B7-H3 tumor antigen. Engineered using the EAGLE Platform for tumor-targeted enzymatic desialylation. In Phase 1 clinical trial for advanced solid tumors (platinum-resistant ovarian cancer) conducted in China via strategic partner Henlius. Demonstrated tumor surface desialylation lasting more than seven days in vivo and outperformed anti-PD-1 as single agent in humanized tumor models.

Quantifiable outcome

  • E-602 demonstrated single-agent antitumor activity and wide safety margin in animal models with NOAEL of 100 mg/kg in non-human primates
  • +3 more outcomes

Companies that use Palleon Pharmaceuticals

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Palleon Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Palleon Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Shanghai Henlius BiotechcoreStrategic or Co-development Partner · 28 June 2022Strategic collaboration to develop and commercialize two bifunctional sialidase programs from Palleon's EAGLE platform, including Bifunctional HER2-Sialidase and a second bifunctional sialidase. Henlius received exclusive license for two products in China (including Hong Kong, Macau, and Taiwan); Palleon retains all other global rights. Palleon received upfront payment and is eligible for up to $196.5 million in milestone payments plus royalties.
  • Massachusetts General HospitalminorStrategic or Co-development Partner · 9 April 2021Research collaboration using Palleon's HYDRA technology to quantify immunosuppressive sialoglycans in melanoma tumor samples.
  • King's College LondoncoreTechnology or Integration · 12 December 2017Exclusive license agreement for intellectual property developed by Professor Joy Burchell related to glycoimmune checkpoints for treating cancer. Professor Burchelli has been a leader in aberrant glycosylation in breast cancer for over 25 years.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Palleon Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Innate Pharma: Clinical-stage immuno-oncology company developing antibody-based therapeutics targeting innate immune cells. Comparable to Palleon in stage, I/O modality innovation, and European/U.S. clinical focus, though Innate targets NK and myeloid checkpoints rather than glyco-immune checkpoints.
  • Werewolf Therapeutics: Clinical-stage oncology biotech developing tumor-activated immunotherapies (PREDATOR platform) that conditionally activate within the tumor microenvironment. Comparable to Palleon in its I/O modality innovation approach and clinical-stage development profile.
  • Compass Therapeutics: Clinical-stage oncology company developing novel antibodies for I/O, including bispecifics and antibody-drug conjugates. Similar in clinical-stage development, novel checkpoint engagement, and I/O competitive positioning to Palleon's EAGLE platform output.
  • Xilio Therapeutics: Clinical-stage biotech developing tumor-activated immunotherapies (including masked cytokines and bispecifics) that are designed to be activated selectively in the tumor microenvironment. Directly comparable clinical-stage I/O peer with similar novel-modality approach.
  • Surface Oncology: Clinical-stage immuno-oncology company developing antibodies targeting novel immune checkpoints (CD39, CD73, IL-27). Comparable in clinical stage and focus on next-generation checkpoint mechanisms beyond PD-1/L1, though Surface targets the adenosine pathway rather than glycans.
  • Anaveon: Clinical-stage biotech developing engineered cytokine therapeutics (selective IL-2 and IL-15 agonists) for cancer immunotherapy. Comparable as a clinical-stage I/O company engineering novel immunomodulatory biologics, with similar size and development profile.
  • Pyxis Oncology: Clinical-stage oncology company developing antibody-drug conjugates and immunotherapies. Comparable clinical-stage peer in novel oncology therapeutic modalities, though Pyxis focuses on ADCs rather than enzyme-based glyco-immune approaches.
  • Alector: Clinical-stage immunology company developing antibodies targeting the innate immune system for neurodegeneration and oncology. Comparable as a science-driven immunology platform company with deep academic founder involvement, though Alector primarily targets neurodegenerative diseases.

Broad incumbents

  • Genmab: Established antibody therapeutics company with approved products (Darzalex, Tepezza) and broad I/O pipeline. Relevant as a broader incumbent in antibody-based I/O modalities that competes for the same BD, talent, and capital pools as Palleon's bifunctional sialidase programs.

Emerging players

  • Disc Medicine: Clinical-stage biotech developing therapeutics for hematologic diseases with novel mechanisms. Comparable as a similar-sized, science-led clinical-stage biotech with a focus on hematology-adjacent indications, though Disc targets erythroid biology rather than glyco-immune checkpoints.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Palleon Pharmaceuticals social profiles

Digital presence

Palleon Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Palleon Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles6 records

Palleon Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Palleon Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Palleon Pharmaceuticals

What does Palleon Pharmaceuticals do?

Palleon Pharmaceuticals is a clinical-stage biopharmaceutical company developing first-in-class glyco-immune checkpoint inhibitors for the treatment of cancer and autoimmune diseases. The company uses proprietary engineered human sialidase enzymes (via the EAGLE, CONVERGENCE, and HYDRA platforms) to enzymatically remove immunosuppressive sialic acids from tumor and immune cell surfaces, restoring anti-tumor immunity. Lead clinical assets include E-602 (Phase 2 for membranous nephropathy/autoimmune disease; previously Phase 1/2 for solid tumors) and E-688/HLX316 (Phase 1 for advanced solid tumors in China).

Is Palleon Pharmaceuticals a public or private company?

Palleon Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Palleon Pharmaceuticals founded?

Palleon Pharmaceuticals was founded in 2015. It employs 11 to 50 people.

Where is Palleon Pharmaceuticals based?

Palleon Pharmaceuticals is headquartered in Waltham, United States, in the North America region.

How does Palleon Pharmaceuticals make money?

One revenue line is on record: pharmaceutical Development and Commercialization.

Who are Palleon Pharmaceuticals's main competitors?

Direct peers on record are Innate Pharma, Werewolf Therapeutics, Compass Therapeutics, Xilio Therapeutics, Surface Oncology, Anaveon, Pyxis Oncology and Alector. Genmab is listed as a broad incumbent. Disc Medicine is listed as an emerging player.

Does Palleon Pharmaceuticals have an API?

No public API is recorded for Palleon Pharmaceuticals.

What industry is Palleon Pharmaceuticals in?

Palleon Pharmaceuticals's product category is Clinical-stage Biopharmaceuticals - Glyco-immune Checkpoint Inhibitors. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins, with a secondary code of HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogPalleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ACR Convergence 2026Palleon Pharmaceuticals presented Phase 2 results for HLX79/E-602 plus rituximab in primary membranous nephropathy at ACR Convergence 2026. The combination achieved complete or partial remission in a median of 3 weeks versus 11 weeks for rituximab alone, with 100% remission at week 36 versus 50%. The company says the mechanism may apply to other autoimmune diseases.FinancialContent Business PagePalleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ACR Convergence 2026Palleon Pharmaceuticals presented Phase 2 data for HLX79/E-602 plus rituximab in primary membranous nephropathy at ACR Convergence 2026. The combination achieved complete or partial remission in a median of 3 weeks versus 11 weeks for rituximab alone, with 100% remission at week 36 versus 50%. The company cites a potential mechanism applicable to other autoimmune diseases.Business Wire BlogPalleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ASN Kidney Week 2026Palleon Pharmaceuticals presented Phase 2 results for HLX79/E-602 plus rituximab in primary membranous nephropathy at ASN Kidney Week 2026. The combination produced faster responses and higher remission rates than rituximab alone, with 100% of patients responding at week 36 versus 50% for rituximab alone. The therapy was well-tolerated in an outpatient setting.FinancialContent Business PagePalleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ASN Kidney Week 2026Palleon Pharmaceuticals presented Phase 2 results for HLX79/E-602 plus rituximab in primary membranous nephropathy at ASN Kidney Week 2026. The combination achieved faster responses and higher remission rates than rituximab alone, with 100% of patients in remission at week 36 versus 50% for rituximab alone. The therapy was well-tolerated in an outpatient setting.Business Wire BlogPalleon Pharmaceuticals Announces Oral Presentation of Interim Phase 2 trial data for HLX79/E-602 in Membranous Nephropathy at the 2026 American College of Rheumatology (ACR) ConvergencePalleon Pharmaceuticals will present interim Phase 2 data for HLX79/E-602, a first-in-class human sialidase-Fc fusion protein, in membranous nephropathy at the 2026 ACR Convergence on November 11. The oral presentation, led by CEO Jim Broderick, will be available on the company's Glycobiology Education section.FinancialContent Business PagePalleon Pharmaceuticals Announces Late-Breaking Oral Presentation on HLX79/E-602 in Autoimmune Disease at the 2026 American Society of Nephrology (ASN) Kidney WeekPalleon Pharmaceuticals will present HLX79/E-602, a first-in-class sialidase enzyme, at ASN Kidney Week on October 23 in Denver. The oral presentation, titled 'HLX79 Plus Rituximab Produces Fast and Durable Responses in Patients with Membranous Nephropathy,' will be delivered by Brad Rovin, M.D.Business Wire BlogPalleon Pharmaceuticals Announces Late-Breaking Oral Presentation on HLX79/E-602 in Autoimmune Disease at the 2026 American Society of Nephrology (ASN) Kidney WeekPalleon Pharmaceuticals will present HLX79/E-602, a first-in-class sialidase enzyme, at ASN Kidney Week on October 23. The oral presentation will update data on the drug's fast and durable responses in patients with membranous nephropathy.BioSpacePalleon Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of E-688/HLX316, a First-in-Class B7-H3-Targeted Sialidase for Advanced Solid TumorsPalleon Pharmaceuticals announced that the first patient has been dosed in a Phase 1 clinical trial for E-688/HLX316, a first-in-class B7-H3-targeted sialidase for advanced solid tumors. The trial is being conducted in China by strategic partner Shanghai Henlius Biotech, focusing initially on platinum-resistant ovarian cancer patients. This milestone marks the clinical translation of Palleon's glycan editing science to restore anti-tumor immunity.BioSpacePalleon Pharmaceuticals Presents First-in-Class B7-H3 Targeted Sialidase at the 2026 AACR Annual MeetingPalleon Pharmaceuticals presented preclinical data and announced the initiation of a first-in-human clinical trial for E-688/HLX316, a B7-H3 targeted sialidase, at the 2026 AACR Annual Meeting. The trial, led by collaborator Henlius in China, targets platinum-resistant ovarian cancer, with preclinical data showing extended tumor desialylation and superior anti-tumor immunity compared to anti-PD-1.Business Wire BlogPalleon Pharmaceuticals Presents First-in-Class B7-H3 Targeted Sialidase at the 2026 AACR Annual MeetingPalleon Pharmaceuticals presented preclinical data for E-688/HLX316, a first-in-class B7-H3 targeted sialidase, at the 2026 AACR Annual Meeting and announced the initiation of its first-in-human clinical trial in China. The trial is being led by strategic collaborator Henlius following IND approval from the National Medical Products Administration (NMPA). This development marks the entry of the first tumor-targeted enzymatic desialylation agent into clinical testing.